ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning:...


ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs